What will the average number of measles cases be during Trump's term?
Based on current outbreak trajectory and likely vaccination/epidemiological dynamics, I assess a high probability that the measured average number of US measles cases during 2025–2028 will meet the market's 'Yes' condition (see assumptions below). My independent probability: 72%.
Analysis
**Assumption / clarification (critical):** the binary "Yes" in the market is interpreted here as the average annual number of confirmed US measles cases during the Trump Administration (calendar years 2025–2028) exceeding the recent low-baseline and/or a meaningful threshold consistent with current outbreak conditions (operationalized in my thinking as >1,000 cases/year on average). If the market's threshold is materially different, adjust the numbers below accordingly.
Stage 1 — BLIND ANALYSIS (ignore current market prices)
- Current evidence: as of July 2, 2026 there are 2,170 confirmed measles cases in the US for 2026. That number covers roughly the first half of 2026, implying an annualized pace well above 3,000–4,000 cases if transmission remains similar through the rest of the year. Historical context: large US outbreaks (e.g., 2019) produced ~1,200+ cases; the 2026 partial-year total already outstrips that pace.
- Epidemiological drivers pointing to a high multi-year average: - **Large susceptible pool**: reductions in routine MMR coverage in some states and pockets of under-vaccination create recurring outbreak risk rather than a single-year spike. Waning immunity in certain populations and birth cohorts without catch-up immunization exacerbate this. - **Transmission momentum**: widespread community transmission by mid-2026 increases the chance of repeated outbreaks and seedings in subsequent years across multiple states. - **International importations**: global measles circulation remains substantial in multiple regions; imports can repeatedly spark domestic outbreaks when pockets of susceptibility exist.
- Countervailing factors that could limit multi-year averages: - Rapid public-health response (surge vaccination campaigns, shortened reporting delays) can sharply reduce future case counts. Large outbreaks often prompt intensive catch-up campaigns that reduce susceptibility fast. - Natural immunity from a big outbreak temporarily reduces susceptible fraction, creating multi-year dips after a spike. - Surveillance/reporting artefacts: if 2026 case-count inflation is partly due to concentrated, well-detected clusters (e.g., in states with aggressive testing), the rest of the term might show lower counts.
- Integrative blind judgment: given the mid-2026 trajectory (2,170 confirmed by early July), the most plausible independent view is that the average annual case count across 2025–2028 will be elevated relative to recent historical baselines and exceed a 1,000-case/year threshold. I place the pure evidence-driven probability at **~72%** that the 'Yes' condition holds (i.e., the average exceeds the threshold described above). This reflects: high current incidence, likelihood of continued outbreaks in 2026–2027, but tempered by possible strong public-health responses and depletion of susceptibles after large outbreaks.
Stage 2 — MARKET CALIBRATION (incorporate market prices)
- Current market: Yes 0.30 | No 0.70 (volume substantive ~148k contracts). The market is assigning a substantially lower probability to the 'Yes' outcome than my blind estimate.
- Why the market may be pricing lower than my independent estimate: 1. **Different threshold interpretation**: market participants may be using a higher line (e.g., average >2,000 or >3,000) than my >1,000 operational threshold — if so, a lower Yes price is consistent. Clarify the contract's resolution metric before trading. 2. **Mean reversion expectations**: traders may expect a big 2026 spike to be followed by low 2027–2028 counts (rapid depletion of susceptibles + aggressive vaccination), bringing the average down. Markets often overweight regulatory/response effects. 3. **Data uncertainty / reporting lag**: some participants may discount partial-year 2026 data or believe 2,170 includes probable cases that will be later reclassified. 4. **Liquidity and behavioral factors**: the sizable volume suggests established positions; large holders with conviction selling Yes could suppress price even if fundamentals favor Yes.
- Why the market may be underpricing Yes (my read): the mid-year 2026 pace is large enough that even with plausible reductions in later years, the 4-year average is likely to stay above conservative thresholds. If the market is using a moderate threshold (1,000–1,500 average), the current price implies participants are too optimistic about rapid sustained suppression.
- Conclusion of calibration: I retain my independent 72% estimate. If the contract's true threshold is at/near the >1,000/year level, the market at 30% looks materially mispriced; if the threshold is much higher (>2,500 average), the market price may be closer to fair. Before acting on the market, confirm the resolution threshold precisely.
Arguments
For
- Argument for Yes 1: The first-half 2026 total (2,170) annualizes to a multi-thousand-case year if transmission persists; that alone strongly elevates a 4-year average.
- Argument for Yes 2: Persistent pockets of low vaccination and international importations make repeated outbreaks across multiple years likely rather than a single isolated spike.
- Argument for Yes 3: Political and social factors that reduce routine childhood immunization uptake can sustain higher baseline measles incidence across the 2025–2028 period.
Against
- Argument against 1: Large outbreaks commonly trigger intensive catch-up vaccination efforts that can quickly reduce incidence in subsequent years, lowering the multi-year average.
- Argument against 2: Natural immunity acquired during a large outbreak can temporarily reduce susceptible individuals and produce several low-incidence years after a spike.
- Argument against 3: If the market's 'Yes' threshold is substantially larger than my working threshold, the observed mid-2026 figures may be insufficient to force a long-term above-threshold average.
Key drivers
- Mid-2026 confirmed cases (2,170 by July 2) and whether that pace continues through year-end
- Vaccination catch-up campaigns and state/local public-health response intensity
- Size and geographic clustering of under-vaccinated populations (persistent pockets of susceptibility)
- International importation rates and global measles circulation
Risk factors
- Aggressive, well-resourced outbreak response that rapidly increases MMR coverage in high-risk areas
- Depletion of susceptibles after a very large outbreak leading to lower incidence in subsequent years
- Changes in case definition, reporting practices, or later reclassification reducing confirmed totals
- Uncertainty about the market's resolution threshold (misalignment between my assumed threshold and the contract)
Scenarios
Best case
For the 'Yes' outcome: Outbreak momentum continues through late 2026 with multiple large clusters in 2026–2027, vaccination responses are slower or patchy, and importations keep occurring — producing a high multi-year average (e.g., several thousand cases/year), firmly resolving the contract as Yes.
Most likely
A mixed path: 2026 finishes substantially above historically low baselines (annualized several thousand cases), 2027 declines as public-health interventions and immunity reduce transmission, and 2028 is moderate — resulting in an average that is elevated compared to pre-2025 levels and, under a moderate threshold (>1,000/year), resolves to Yes; under a higher threshold (>2,500/year) it may fall short and resolve to No.
Worst case
For the No outcome: A decisive, well-coordinated national and state response quickly conducts catch-up campaigns in mid-to-late 2026, reducing susceptible pockets; 2027–2028 see low incidence due to both vaccination and post-outbreak immunity, pulling the 4-year average below the contract threshold and resolving to No.
More from this day
- PoliticsKalshi2y
Which agencies will Trump eliminate?
AI99%MKT32%Edge+67Hidden GemUSAID has already been functionally eliminated as an independent agency (shuttered July 1, 2025 and folded into State); I assess a ~99% chance it will be counted as eliminated during Trump’s term.
- PoliticsKalshi18y
Which G7 leader will leave next?
AI35%MKT98%Edge-63HypedI assess ~35% chance the UK Prime Minister (Keir Starmer) will be the first G7 leader to leave office; the market at ~98% for that outcome looks severely overstated given scheduled election timing and relative stability of other leaders.
- PoliticsKalshi2y
Which Supreme Court justices will resign during Trump's term?
AI8%MKT63%Edge-55HypedIndependent assessment: very unlikely that Justice Samuel Alito will resign during Trump's 2025–2029 term; I estimate an 8% chance he voluntarily resigns during that window.